Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 3/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.35 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14234316 | 1.00 | FURIN (0.42) | FURINHTTSMN1; SMN2SPHK1POLB | |
| SCHEMBL24728301 | 1.00 | FURIN (0.42) | FURINHTTSMN1; SMN2SPHK1POLB | |
| SCHEMBL21965275 | 0.97 | FURIN (0.41) | FURINHTTSMN1; SMN2SPHK1SIRT1 | |
| SCHEMBL27291528 | 0.92 | FURIN (0.49) | FURINHTTSMN1; SMN2SPHK1POLB | |
| SCHEMBL17133811 | 0.91 | FURIN (0.45) | FURINHTTSMN1; SMN2POLBLMNA | |
| SCHEMBL21122921 | 0.91 | FURIN (0.41) | FURINHTTSMN1; SMN2POLBLMNA | |
| SCHEMBL17133812 | 0.91 | FURIN (0.45) | FURINHTTSMN1; SMN2POLBLMNA | |
| SCHEMBL24414345 | 0.91 | FURIN (0.41) | FURINHTTSMN1; SMN2SPHK1POLB | |
| SCHEMBL16847753 | 0.91 | FURIN (0.43) | FURINHTTSMN1; SMN2POLBLMNA | |
| SCHEMBL23386894 | 0.90 | SPHK1 (0.45) | FURINHTTSPHK1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023061457-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | 百奥泰生物制药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2022253284-A1 | DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | FURIN 7/4885HTT 4454/4885SMN1; SMN2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.